Phase Ib clinical trial on another TLR9 agonist, CMP-001, administered alone or in combination with pembrolizumab in patients with anti-PD-L1-resistant malignant melanoma showed that the response rate of the combination therapy was 25% (28/83), with CR in six patients and partial response (PR) in 22 patients. Here, TLR9 is linked to melanoma.